PremiumCompany AnnouncementsEli Lilly Advances EMERALD-3: A New Oral Bet in Ulcerative Colitis6h agoLLY
PremiumCompany AnnouncementsEli Lilly Refines Mirikizumab Delivery With New Phase 1 Injection Study6h agoLLY
PremiumCompany AnnouncementsEli Lilly Targets Crohn’s Disease With New Combo Trial That Could Extend Its IBD Franchise6h agoLLY
PremiumCompany AnnouncementsEli Lilly Launches Master IBD Study, Expanding Its Bet on Ulcerative Colitis and Crohn’s Therapies6h agoLLY